CO4910156A1 - Metodos y composiciones para inhibir la liberacion de pepti- do beta-amiloide y/o su sintesis - Google Patents

Metodos y composiciones para inhibir la liberacion de pepti- do beta-amiloide y/o su sintesis

Info

Publication number
CO4910156A1
CO4910156A1 CO97068215A CO97068215A CO4910156A1 CO 4910156 A1 CO4910156 A1 CO 4910156A1 CO 97068215 A CO97068215 A CO 97068215A CO 97068215 A CO97068215 A CO 97068215A CO 4910156 A1 CO4910156 A1 CO 4910156A1
Authority
CO
Colombia
Prior art keywords
substituted
alkyl
group
aryl
alkynyl
Prior art date
Application number
CO97068215A
Other languages
English (en)
Spanish (es)
Inventor
Thomas C Britton
James J Droste
K Folmer Beverly
George W Huffman
John Vorghese
H Latimer Lee
Thomas E Mabry
S Nissen Jeffrey
J Porter Warren
Jon K Reel
Eugene D Thorsett
Jay S Tung
Wu Jing
Norman Eid Clark
William Leonard Scott
Original Assignee
Lilly Co Eli
Athena Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Athena Neurosciences Inc filed Critical Lilly Co Eli
Publication of CO4910156A1 publication Critical patent/CO4910156A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
CO97068215A 1996-11-22 1997-11-21 Metodos y composiciones para inhibir la liberacion de pepti- do beta-amiloide y/o su sintesis CO4910156A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75544296A 1996-11-22 1996-11-22
US80852897A 1997-02-28 1997-02-28
US80752897A 1997-02-28 1997-02-28
US80742797A 1997-02-28 1997-02-28

Publications (1)

Publication Number Publication Date
CO4910156A1 true CO4910156A1 (es) 2000-04-24

Family

ID=27505670

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97068215A CO4910156A1 (es) 1996-11-22 1997-11-21 Metodos y composiciones para inhibir la liberacion de pepti- do beta-amiloide y/o su sintesis

Country Status (21)

Country Link
EP (1) EP0942924A2 (fr)
JP (1) JP2001503782A (fr)
KR (1) KR20000069064A (fr)
CN (1) CN1238779A (fr)
AR (1) AR016751A1 (fr)
AU (1) AU5356198A (fr)
BR (1) BR9713400A (fr)
CA (1) CA2267634A1 (fr)
CO (1) CO4910156A1 (fr)
CZ (1) CZ122899A3 (fr)
EA (1) EA199900490A1 (fr)
HR (1) HRP970627A2 (fr)
HU (1) HUP0100270A3 (fr)
ID (1) ID22044A (fr)
IL (1) IL129083A0 (fr)
NO (1) NO992368L (fr)
NZ (1) NZ334690A (fr)
PE (1) PE16999A1 (fr)
TR (3) TR199902937T2 (fr)
WO (1) WO1998022494A2 (fr)
YU (1) YU46097A (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6191166B1 (en) * 1997-11-21 2001-02-20 Elan Pharmaceuticals, Inc. Methods and compounds for inhibiting β-amyloid peptide release and/or its synthesis
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
JP2002518483A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチド放出を阻害するための化合物および／またはその合成
US6958330B1 (en) 1998-06-22 2005-10-25 Elan Pharmaceuticals, Inc. Polycyclic α-amino-ε-caprolactams and related compounds
WO1999066934A1 (fr) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. COMPOSES D'ACIDES AMINES CYCLIQUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET METHODES D'INHIBITION DE LA LIBERATION DU PEPTIDE β-AMYLOIDE ET/OU DE SA SYNTHESE A L'AIDE DE CES COMPOSES
US6552013B1 (en) 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
EP1089977A1 (fr) * 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19834591A1 (de) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Verfahren zur Steigerung des Blutglukosespiegels in Säugern
US6486350B1 (en) 1998-09-30 2002-11-26 Elan Pharmaceuticals Inc. Biological reagents and methods for determining the mechanism in the generation of β-amyloid peptide
US6737038B1 (en) 1998-11-12 2004-05-18 Bristol-Myers Squibb Company Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging
JP2002531576A (ja) 1998-12-10 2002-09-24 エフ．ホフマン−ラ ロシュ アーゲー プロコラーゲンｃ−プロテイナーゼ阻害剤
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
RO121640B1 (ro) * 1999-05-07 2008-01-30 Texas Biotechnology Corporation Derivaţi de acid propionic ce inhibă legarea integrinelor de receptorii acestora, compoziţie farmaceutică ce îi conţine şi utilizare a acesteia
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
DE19926233C1 (de) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Verfahren zur Herstellung von Thiazolidin
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
WO2001034639A2 (fr) * 1999-11-09 2001-05-17 Eli Lilly And Company COMPOSES CONTENANT DES β-ACIDES AMINES UTILES POUR INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
EP2055302B1 (fr) 2000-03-31 2014-09-10 Royalty Pharma Collection Trust Procédé d'amélioration de signalisation d'îlots dans le diabète sucré et pour sa prévention
AU2001261728A1 (en) 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
IL147629A0 (en) 2000-06-01 2002-08-14 Bristol Myers Squibb Pharma Co LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
FR2832152A1 (fr) * 2001-11-09 2003-05-16 Aventis Pharma Sa Utilisation de derives de 2-amino-thiazoline comme inhibiteurs de no-synthase inductible
GB0016681D0 (en) 2000-07-06 2000-08-23 Merck Sharp & Dohme Therapeutic compounds
US6432944B1 (en) 2000-07-06 2002-08-13 Bristol-Myers Squibb Company Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
DE10150203A1 (de) 2001-10-12 2003-04-17 Probiodrug Ag Peptidylketone als Inhibitoren der DPIV
FR2840899B1 (fr) * 2002-06-12 2005-02-25 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
DE10143840A1 (de) * 2001-09-06 2003-03-27 Probiodrug Ag Neue Inhibitoren der Dipeptidylpeptidase I
BR0206354A (pt) 2001-11-09 2003-12-23 Aventis Pharma Sa Utilização de derivados de 2-amino-tiazolina como inibidores de no-sintase indutìvel
SK3622004A3 (sk) 2002-02-28 2005-02-04 Prosidion Limited Inhibítory DPIV na báze glutaminylu
CN1777577B (zh) 2003-01-08 2011-07-06 诺华疫苗和诊断公司 抗菌剂
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
CN101837127A (zh) 2003-05-05 2010-09-22 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
WO2005027969A1 (fr) * 2003-09-24 2005-03-31 Santen Pharmaceutical Co., Ltd. Remede pour maladies des yeux accompagnees de blessures du nerf optique
WO2005039548A2 (fr) 2003-10-15 2005-05-06 Probiodrug Ag Utilisation d'effecteurs de cyclases du glutaminyle et du glutamate
CN101765585B (zh) 2007-06-12 2017-03-15 尔察祯有限公司 抗菌剂
EP2062909A1 (fr) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Production de peptides et procédé de purification
BG110141A (en) 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
WO2013170165A1 (fr) 2012-05-10 2013-11-14 Achaogen, Inc. Agents antibactériens
WO2017004560A1 (fr) * 2015-07-02 2017-01-05 The Regents Of The University Of California Procédés et compositions pour des agrégats amyloïdes
US20240010642A1 (en) * 2021-01-05 2024-01-11 Southern Research Institute Modulators of programmed death-ligand-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518955A4 (en) * 1990-03-05 1993-09-22 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
WO1995013084A1 (fr) * 1992-05-11 1995-05-18 Miles Inc. Identification de la cathepsine d comme protease amyloïdogene de la maladie d'alzheimer
IL110525A0 (en) * 1993-08-09 1994-11-11 Lilly Co Eli Identification and use of protease inhibitors
AU687449B2 (en) * 1993-10-01 1998-02-26 Aventis Inc. Inhibitors of beta-amyloid protein production
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
CA2221684A1 (fr) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Nouvelle cathepsine et procedes et compositions d'inhibition de cathepsine

Also Published As

Publication number Publication date
TR199902938T2 (xx) 2002-06-21
TR199901133T2 (xx) 1999-07-21
WO1998022494A3 (fr) 1998-11-26
IL129083A0 (en) 2000-02-17
EA199900490A1 (ru) 2000-02-28
KR20000069064A (ko) 2000-11-25
NO992368L (no) 1999-06-21
AR016751A1 (es) 2001-08-01
JP2001503782A (ja) 2001-03-21
NO992368D0 (no) 1999-05-14
AU5356198A (en) 1998-06-10
NZ334690A (en) 2001-09-28
CA2267634A1 (fr) 1998-05-28
HRP970627A2 (en) 1998-08-31
PE16999A1 (es) 1999-02-19
BR9713400A (pt) 2000-01-25
WO1998022494A2 (fr) 1998-05-28
TR199902937T2 (xx) 2001-01-22
CZ122899A3 (cs) 1999-10-13
ID22044A (id) 1999-08-26
HUP0100270A3 (en) 2001-09-28
YU46097A (sh) 2000-10-30
HUP0100270A2 (hu) 2001-08-28
CN1238779A (zh) 1999-12-15
EP0942924A2 (fr) 1999-09-22

Similar Documents

Publication Publication Date Title
CO4910156A1 (es) Metodos y composiciones para inhibir la liberacion de pepti- do beta-amiloide y/o su sintesis
DK0915866T3 (da) Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre
ZA921804B (en) Cyclic urea derivatives, pharmaceutical compositions containing these compounds and processes for preparing them.
IL135536A0 (en) Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
BR9708389B1 (pt) compostos de piperazina e piperidina, composições farmacêuticas.
ATE1906T1 (de) Glucosamin-peptid-derivate, ihre herstellung und verwendung.
IE41528L (en) Furfuryl-benzomorphane derivatives.
ES2122258T3 (es) 4-azaesteroides 15 sustituidos.
BG104445A (en) NOVEL 3,6-HEMIKETALS FROM THE CLASS OF 9a-AZALIDES
GB1120463A (en) Derivatives of 1,3-diazafluoranthene-1-oxide
ATE409180T1 (de) Synthese von zyklopentadien derivaten
GB961037A (en) Pyrazolones and processes for their preparation
IL69882A (en) Analgesia-effecting 5-hydroxytryptophan derivatives and pharmaceutical compositions comprising them
IE45590L (en) Anilines.
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
HUP9904514A2 (hu) 5H-Pirrolo[2,1-c][1,4]-benzodiazepin-3-karboxamid-származékok, eljárás előállításukra, alkalmazásuk és az azokat tartalmazó gyógyszerkészítmények
PT763024E (pt) Novos processos e intermediarios para a preparacao de derivados de piperazina
CO4970802A1 (es) Compuesto bencimidazol-5 sustituido con estabilidad mejorada
GB1075251A (en) Cardenolide derivatives
ES8701174A1 (es) Un metodo de preparacion de un compuesto de tiadiazina
CY1106058T1 (el) Σταθερες συνθεσεις οξαπενεμ-3-καρβοξυλικων οξεων με συν-λυοφιλοποιηση με φαρμακευτικους φορεις
KR860009035A (ko) 11-β 치환된 스테로이드의 제조방법
CA1273946C (fr) Derives de gamma-thiobutyrolactone anticonvulsivant
NZ237066A (en) Indole derivatives and pharmaceutical preparations
ES458481A1 (es) Un procedimiento de preparacion de nuevos derivados de ben- zodiazepina.